Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Status: Enrolling
Updated:  12/31/1969
University of Michigan Hospitals /ID# 161265
mi
from
Ann Arbor, MI
A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Status: Enrolling
Updated: 12/31/1969
University of Michigan Hospitals /ID# 161265
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Status: Enrolling
Updated:  12/31/1969
Northwest Gastroenterology Cli /ID# 161257
mi
from
Portland, OR
A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Status: Enrolling
Updated: 12/31/1969
Northwest Gastroenterology Cli /ID# 161257
mi
from
Portland, OR
Click here to add this to my saved trials
A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Status: Enrolling
Updated:  12/31/1969
Liver Associates of Texas, P.A. /ID# 161262
mi
from
Houston, TX
A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Status: Enrolling
Updated: 12/31/1969
Liver Associates of Texas, P.A. /ID# 161262
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Status: Enrolling
Updated:  12/31/1969
University of Vermont Medical Center /ID# 161263
mi
from
Burlington, VT
A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Status: Enrolling
Updated: 12/31/1969
University of Vermont Medical Center /ID# 161263
mi
from
Burlington, VT
Click here to add this to my saved trials
A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Status: Enrolling
Updated:  12/31/1969
Digestive and Liver Disease Sp /ID# 161259
mi
from
Norfolk, VA
A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Status: Enrolling
Updated: 12/31/1969
Digestive and Liver Disease Sp /ID# 161259
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Status: Enrolling
Updated:  12/31/1969
DCC Aleksandrovska /ID# 161340
mi
from
?????,
A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment
A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1
Status: Enrolling
Updated: 12/31/1969
DCC Aleksandrovska /ID# 161340
mi
from
?????,
Click here to add this to my saved trials
Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics
Interventions to Increase HBV Vaccinations in STD Clinics
Status: Enrolling
Updated:  12/31/1969
Chicago Department of Public Health
mi
from
Chicago, IL
Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics
Interventions to Increase HBV Vaccinations in STD Clinics
Status: Enrolling
Updated: 12/31/1969
Chicago Department of Public Health
mi
from
Chicago, IL
Click here to add this to my saved trials
Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics
Interventions to Increase HBV Vaccinations in STD Clinics
Status: Enrolling
Updated:  12/31/1969
Bell Flower Clinic
mi
from
Indianapolis, IN
Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics
Interventions to Increase HBV Vaccinations in STD Clinics
Status: Enrolling
Updated: 12/31/1969
Bell Flower Clinic
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Hepatitis C Testing in VA Community-Based Outpatient Clinics
Hepatitis C Testing in VA Community-Based Outpatient Clinics (QUE 15-284)
Status: Enrolling
Updated:  12/31/1969
Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA
mi
from
Bedford, MA
Hepatitis C Testing in VA Community-Based Outpatient Clinics
Hepatitis C Testing in VA Community-Based Outpatient Clinics (QUE 15-284)
Status: Enrolling
Updated: 12/31/1969
Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA
mi
from
Bedford, MA
Click here to add this to my saved trials
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
Status: Enrolling
Updated:  12/31/1969
Stanford LPCH Vaccine Program
mi
from
Stanford, CA
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
Status: Enrolling
Updated: 12/31/1969
Stanford LPCH Vaccine Program
mi
from
Stanford, CA
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Palo Alto, CA
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pasadena, CA
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pasadena, CA
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Jose, CA
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Jose, CA
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Novi, MI
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Novi, MI
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Flushing, NY
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Flushing, NY
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sugar Land, TX
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated:  12/31/1969
Site Reference ID/Investigator# 8941
mi
from
Edmonton,
Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed
Status: Enrolling
Updated: 12/31/1969
Site Reference ID/Investigator# 8941
mi
from
Edmonton,
Click here to add this to my saved trials
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Status: Enrolling
Updated:  12/31/1969
New York University Langone Medical Center
mi
from
New York, NY
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Status: Enrolling
Updated: 12/31/1969
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Status: Enrolling
Updated:  12/31/1969
SSM Health Dean Medical Group
mi
from
Madison, WI
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Status: Enrolling
Updated: 12/31/1969
SSM Health Dean Medical Group
mi
from
Madison, WI
Click here to add this to my saved trials
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Status: Enrolling
Updated:  12/31/1969
East Sydney Doctors
mi
from
Sydney,
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Status: Enrolling
Updated: 12/31/1969
East Sydney Doctors
mi
from
Sydney,
Click here to add this to my saved trials
Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)
A Prospective, Open-Label, Single-Arm Clinical Trial to Assess the Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety of a Single Intramuscular Dose of a Polyvalent Human Immune Globulin in HAV Seronegative Healthy Subjects
Status: Enrolling
Updated:  12/31/1969
Vince and Associates Clinical Research
mi
from
Overland Park, KA
Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)
A Prospective, Open-Label, Single-Arm Clinical Trial to Assess the Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety of a Single Intramuscular Dose of a Polyvalent Human Immune Globulin in HAV Seronegative Healthy Subjects
Status: Enrolling
Updated: 12/31/1969
Vince and Associates Clinical Research
mi
from
Overland Park, KA
Click here to add this to my saved trials
An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH
An Evaluation of the Safety of Intravenous (IV) Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid in Subjects With Nonalcoholic Steatohepatitis (NASH) and Healthy Controls (HC)
Status: Enrolling
Updated:  12/31/1969
Kettering Medical Center
mi
from
Kettering, OH
An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH
An Evaluation of the Safety of Intravenous (IV) Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid in Subjects With Nonalcoholic Steatohepatitis (NASH) and Healthy Controls (HC)
Status: Enrolling
Updated: 12/31/1969
Kettering Medical Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Hepatitis C Infection in World Trade Center Responders
Hepatitis C Infection in World Trade Center Responders
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Hepatitis C Infection in World Trade Center Responders
Hepatitis C Infection in World Trade Center Responders
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Accel Research Sites
mi
from
Birmingham, AL
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Accel Research Sites
mi
from
Birmingham, AL
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Suncoast Research Group, LLC
mi
from
Miami, FL
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Suncoast Research Group, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Atlanta
mi
from
Atlanta, GA
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research
mi
from
Boise, ID
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research
mi
from
Boise, ID
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research
mi
from
Salt Lake City, UT
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Universitair Ziekenhuis Gent
mi
from
Gent,
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Universitair Ziekenhuis Gent
mi
from
Gent,
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
University of Alabama
mi
from
Birmingham, AL
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
Zuckerberg San Francisco General Hospital
mi
from
San Francisco, CA
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
Zuckerberg San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
Peak Gastroenterology Associates
mi
from
Colorado Springs, CO
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
Peak Gastroenterology Associates
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
Denver Health
mi
from
Denver, CO
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
Denver Health
mi
from
Denver, CO
Click here to add this to my saved trials
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated:  12/31/1969
Providence Health System
mi
from
Washington,
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment
Status: Enrolling
Updated: 12/31/1969
Providence Health System
mi
from
Washington,
Click here to add this to my saved trials